Loading clinical trials...
Loading clinical trials...
Phase II Study of Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated CLL/SLL
Conditions
Interventions
Acalabrutinib
Rituximab
Locations
1
United States
University of Rochester
Rochester, New York, United States
Start Date
March 25, 2019
Primary Completion Date
May 19, 2023
Completion Date
May 19, 2023
Last Updated
September 26, 2024
NCT07030400
NCT06043011
NCT06528301
NCT03342144
NCT05168930
NCT04758975
Lead Sponsor
University of Rochester
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions